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Background: Nephropathic Cystinosis, the most common cause of renal Fanconi
syndrome, is a lysosomal transport disorder with an autosomal recessive inheritance
pattern. A large number of mutations inCTNS have been identified as causative to date. A
57 kb deletion encompassing parts of CTNS is most commonly identified in Caucasians
but this allele has not been identified in individuals of Eastern Mediterranean, Middle
Eastern, Persian, or Arab origin to date.
Methods and Results: Implementing whole exome sequencing (WES) in a
consanguineous Iranian family, we identified this large deletion affecting CTNS in
a patient initially presenting with hypokalemic metabolic alkalosis symptoms and
considerable proteinuria.
Conclusion: We show WES is a cost and time efficient genetic diagnostics modality
to identify the underlying molecular pathology in Cystinosis individuals and provide a
summary of all previously reported CTNS alleles in the Middle east population. Our work
also highlights the importance to consider the 57-kb deletion as underlying genetic cause
in non-European populations, including the Middle East. Limited diagnostic modalities
for Cystinosis in developing countries could account for the lack of previously reported
cases in these populations carrying this allele. Further, our findings emphasize the utility
of WES to define genetic causes in clinically poorly defined phenotypes and demonstrate
the requirement of Copy number variation (CNV) analysis of WES data.
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INTRODUCTION
Cystinosis is an autosomal recessive lysosomal storage disorder
(general incidence of 1:100,000–200,000 live births) caused by
mutation of the CTNS gene (1, 2). CTNS locates to chromosome
17p13, contains 12 exons of which ten exons, exon 3–12,
encode for Cystinosin, a protein facilitating cysteine-proton
co-transport out of lysosomes (3, 4). Impaired Cystinosin
function leads to the build-up of intralysosomal cystine crystals
in cells of many different organs, notably the bone marrow,
lymph nodes, kidney, cornea, thyroid, liver and spleen (5).
Based on the age at onset and the severity of clinical disease,
three cystinosis subtypes are distinguished: the most severe
subtype is nephropathic cystinosis (OMIM#219800) which is
also known as infantile onset renal tubular fanconi syndrome
that affects proximal renal tubular function and results in
failure to thrive, polyuria, and polydipsia with a disease onset
between age 6 and 18 months on average. This is also the
most frequent manifestation of cystinosis accounting for up to
95% of all cases (6). End-stage renal disease (ESRD) occurs
often around 10 years of age if untreated (1). The two
other milder subtypes, the nephropathic juvenile (late onset)
subtype (OMIM# 219900) and the ocular non-nephropathic
adult subtype (OMIM#219750) are rarely diagnosed before
adult-hood (7, 8). Genotype-phenotype correlations suggest that
milder adult-onset phenotypes may occur as a result of at least
one milder mutation in comparison to mutations identified
to cause the early-onset phenotype (9). Early diagnosis is
important especially in nephropathic cystinosis as treatment with
aminothiol cysteamine can slow down progression of the renal
phenotype (10).
Commonly followed diagnostic approaches for cystinosis
include measurement of leukocyte cystine, detection of corneal
cystine crystals by the slit lamp examination and molecular
testing of the relatively small CTNS gene (11). Nonetheless,
in some developing countries, cystinosis diagnosis is still
significantly delayed or may not happen due to limited access
to healthcare and likewise limited diagnostic resources. In
most instances, a cystinosis diagnosis in these countries is
made due to (often repetitive) ophthalmological examinations
showing accumulation of cystine crystals in the cornea. To date,
∼120 causative CTNS mutations including small deletions or
insertions, missense, nonsense, and splice site mutations in the
coding regions or adjacent intronic regions as well as in the
CTNS gene promoter have been described (www.hgmd.cf.ac.uk).
Of note, the most common mutation is a large deletion, affecting
the first 10 exons of the CTNS gene in either homozygous
or heterozygous form. This variant is particularly frequent in
Caucasians, accounting for up to 76% of all cases in this group of
individuals (12). The breakpoints of this 57,257 base pair deletion
locate in exon 10 of CTNS and intron 2/3 of TRPV1, resulting
in deletion of large parts of CTNS, all of CARKL/SHPK and
the two non-coding exons of TRPV1 (13). However, in other
populations, this deletion appears a lot less frequent and previous
reports did not identify this allele in cystinosis cases fromMiddle
Eastern countries including Egypt, Iran, Jordan, Turkey, and
Saudi Arabia (14).
In the present study, we used Whole Exome Sequencing
(WES) to identify the underlying molecular cause in an Iranian
subject with metabolic alkalosis. Interestingly, we identified
the previously described 57 kB deletion encompassing CTNS
exon 1–10.
METHODS
DNA Samples
Consent forms were obtained from all the participants of this
study. Ethical approval was obtained from the Ethics committee
of Mashhad University of medical (IR.MUMS.REC.1395.534)
and samples were processed in Nijmegen under the Diagnostic
Innovation Program.Written informed consent from the parents
or legal guardians of the patients/participants for the publication
of their data. Genomic DNA was extracted from EDTA blood
using standard salting out method. The concentration of
DNA was measured by Qubit 2.0 (life technologies, Carlsbad,
CA, USA).
Whole Exome Sequencing
Two micrograms of DNA from the index case was subjected
to WES at Novogene, Hongkong. Illumina HiSeq 2500. Exome
capture was performed using Agilent SureSelect Human All Exon
V6 Kit; sequencing was undertaken on an Illumina HiSeq 2500
Genome Analyzer machine. Paired-end sequencing resulting
in sequences of 150 bases from each end of the fragments
with a fraction_of_target_covered_with_at_least_10x of 99.5%,
of at least 20x of 98.1%, of at least 50x of 87.7% and of
100x of 44.3%. UCSC hg19 was used as a reference genome.
VarScan version 2.2.5 and MuTec and GATK Somatic Indel
Detector were used to detect SNV and InDels, respectively.
Data was filtered for MAF < 1% in public control databases
such as dbSNP, ExAc, and gnomAD (gnomAD, http://gnomad.
broadinstitute.org). subsequently, variants occurring with MAF
> 1% in the Iranome (contains 800 healthy individuals) (http://
www.iranome.ir) were also excluded. The remaining variants
were filtered for known disease causing genes with emphasis on
diseases compatible with the patient phenotype (renal tubular
disorders). We prioritized homozygous variants due to the
autosomal recessive inheritance pattern of disease and known
consanguinity in the family. This did not reveal any variant
in a gene previously associated with a tubular disorder. We
therefore proceeded to visual inspection of the BAM file for
known tubuluopathy genes and detected a large homozygous
deletion encompassing most of CTNS.
PCR and Sanger Sequencing
The visually identified large homozygous deletion encompassing
CARKL/SHPK and the first 10 exons of CTNS found in
the BAM file of the index case was confirmed using PCR
and subsequent Sanger sequencing. Primers were designed
such as the forward primer located in TRPV1 and the
reverse primer located in intron 10 of CTNS gene. AmpliTaq
mastermix (Applied Biosystems) was used according to the
manufacturer’s protocol. A standard amplification program
was used (initial denaturation at 95◦C for 10min; followed
Frontiers in Pediatrics | www.frontiersin.org 2 March 2019 | Volume 7 | Article 89
Najafi et al. Cystinosis in the Middle East
by 35 cycles of denaturing at 94◦C for 30 s, annealing at
58◦C for 30 s, and extension at 72◦C for 3min and final
extension at 72◦C for 7min). PCR products were cleaned using
ExoSAP-IT R© (USB, Cleveland, Ohio, USA) and subsequently
submitted for bidirectional Sanger sequencing using a 3730XL
DNA analyzer (ABI, Foster City). Primers sequences are
available on request.
RESULTS
Our index case was a 1-year-old boy who was the third child
of consanguineous healthy parents of Persian ethnicity from
Iran. He was born after term gestation with birth weight
of 3,200 g (P25-50) and a length of 49.2 cm (P25-50); the
pregnancy and delivery were uncomplicated. At the age of
nearly 5 months, he was hospitalized due to recurrent vomiting,
polydipsia, and polyuria, failure to thrive was noted since the
4th month of life with a length of 62.2 cm (<P3.) weighing
6,800 g (<P3.) at the age of 8 months. On admission, urine
analysis (dip stick) revealed a specific weight of 1,004, urine
pH of 5, glucosuria (+ + +), proteinuria (+), and ketonuria
(+) with no bilirubin, nitrite, or urobilinogene present. Urine
microscopy did not reveal significant hematuria or leucocytes
in the urine. Chemical urine analysis, for example for protein
quantification and protein subtype identification could not be
performed in the admitting center. Venous blood pH was
7.48 (normal range 7.35–7.45), HCO3 16.7 mmol/L (normal
range 22–26 mmol/L), pCO2 22.6 mmHg (normal range 35–
45 mmhg), pO2 55.3 mmHg (normal range >30 mmHg),
and O2 saturation was found to be 91.1%. Serum sodium
was within normal ranges (140 mmol/L) but hypokalemia
(potassium 2.4 mmol/L, normal range 3.6–5.4 mmol/L) was
noted. Creatinine, ferritine, vitamin D, and TSH were within
the normal range. Abdominal ultrasound did not reveal any
abnormalities in the liver, gallbladder, pancreas, spleen, kidneys,
or bladder. The biochemical findings of mild hypokalemic
alkalosis (possibly with a respiratory component indicated by
low CO2 e.g., due to screaming child) together with severe
growth retardation, polydipsia and polyuria as well as the
urine findings suggested a renal tubulopathy such as Bartter
syndrome or Fanconi syndrome. After 1 month of receiving
Polycitra, the patient gained 400 g of weight (P3.) and his
serum potassium level increased to 3 mmol/L while the blood
pH decreased to pH 7.39. However, HCO3 was measured
14.1 mmol/L, urine pH was 6 and glucosuria, proteinuria,
and ketonuria persisted. After 6 months of treatment, serum
potassium was still below the normal range with 3.2 mmol/L.
The patient showed mild hypophosphatemia (3.5 mg/dl)
(normal range 4–7 mg/dl).
An older sibling who passed away previously at the age of
10 years had a medical history of renal transplant rejection,
however the underlying cause of ESRD had not been clearly
defined. An 8 years old sister did not show any kidney or
eye problems (Figure 1). We therefore proceeded to perform
FIGURE 1 | WES identifies a homozygous deletion encompassing large parts of CTNS. (A) Pedigree of the Iranian family, DNA of individual IV3 was analyzed by WES
(arrow) while no DNA of other family members was available. Females are marked with circle, males with square, solid filling marks affected individuals, crossed
symbols marks a deceased individual, double lines between individuals mark a consang. marriage and single lines mark non-consang.-marriages. (B) WES revealed a
large genomic deletion for individual IV.3 encompassing parts of TRPV1, all of CARKL/SHPK and large parts of CTNS as visualized in the BAM file generated from
WES data. Read alignment of a control person is shown above for comparison. (C) Breakpoint confirmation by Sanger sequencing confirms presence of the
homozygous deletion and reveals a random insertion shown in black.
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TABLE 1 | Summary of previously published CTNS causing variants in patients from the Middle-East.
Country Patient genotype Number of
cases
Study
Jordan c.890G>A, p.Trp297* homoz. 2 (17) (17) (1 family in this study was originally from Sudan)
c.829dupA p.Thr277Asnfs*19 het / - 1 (17)
c.829dupA, p.Trp297* het / c.890G>A, (p.Thr277Asnfs*19) 1 (17)
c.829dupA, p.Thr277Asnfs*19 homoz. 2 (17)
Iran c.681G>A, p.Glu227* homoz. 8 (18), 13 (19) (18–20)
c.681G>A, p.Glu227* het. / c.1017G>A, p.Gly339* het. 2 (18)
c.681G>A, p.Glu227* het. / c.923G>A, p.Gly308Glu het. 1 (18)
c.del18_21GACT, p.Thr7Phefs*7 homoz. 2 (20)
c.del18_21GACT, p.Thr7Phefs*7 het. 1 (18)
c.923G>A, p.Gly308Glu homoz. 1 (18)
c.153-155insCT, p.Ala52Leufs*5 homoz. 1 (18)
c.969C>A, p.Asn323Lys het. 4 (20)
c.323delA, p.Gln108Argfs*10 homoz. 3 (20)
c.257-258delCT, p.Ser86Phefs*38 homoz. 2 (20)
c.662dup, p.Gln222Alafs*6 homoz. 1 (20)
c.92dup , p.Val32Argfs*28 homoz. 1 (20)
c.120delC, p.Asn41Thrfs*10 homoz. 2 (20)
c.517T>C, p.Tyr173His homoz. 1 (19)
c.613G>A, p.Asp205Asn homoz. 1 (19)
c.433C>T, p.Gln145* homoz. 1 (19)
c.1015G>A, p.Gly339Arg) homoz. 1 (19)
c.681G>A, p.Glu227* het / c.853-12T>C het. 1 (19)
c.492_515del, p.Leu165_Ala172del homoz. 2 (19)
Egypt c.922G>A, p.Gly308Arg homoz. 1 (21) (21)
c.809_811del, p.Ser270del homoz. 1 (21)
c.15G>A, p.(Trp5*) homoz. 1 (21)
c.681G>A, p.(Glu227* homoz. 1 (21)
c.260_261delTT, p.(Phe87Serfs*37) het. / c.560A>G, p.(Lys187Arg) het. 1 (21)
c.1015G>A, p.(Gly339Arg) homoz. 1 (21)
c.734G>A, p.(Trp245*) het / c.1032delinsTG, p.(Phe345Valfs*85) het. 2 (21)
c.1084G>A, p.(Gly362Arg) het. 1 (21)
c.61+5G>T homoz. 1 (21)
c.829dup, p.(Thr277Asnfs*19) homoz. 4 (21)
Turkey c.451A>G, p.Arg151Gly het./ c.1015G>A, p.(Gly339Arg het. 2 (22), (23) (14, 22–25)
c.del18_21GACT, p.Thr7Phefs*7 homoz. 3 (22), (23)
c.140+1G>T homoz. 1 (22)
c.518A>G, p.Val171Ala homoz. 1 (22)
c.681G>A, p.Glu227* het / c.1015G>A, p.Gly339Arg het. 1 (22)
c.681G>A, p.Glu227* homoz. 10 (22), (23), (24)
c.del18_21GACT, p.(Thr7Phefs*7) het/ c.470G>A, p.(Gly157Asp) het. 1 (22)
c.62-1083_551del homoz. 1 (22)
c.451A>G, p.Arg151Gly homoz. 10 (22, 23)
c.141-22A>G het/ c.681G>A, p.Glu227* het. 2 (22)
c.834_842del, p. Val279_Tyr281del homoz. 6 (23)
c.325_329del, p.(Thr109Profs*14) homoz 1 (24)
c.960del, p.Tyr321Thrfs*8 homoz. 1 (14)
c.853-1G>A homoz. 1 (14)
c.664C>T, p.Gln222* homoz. 1 (14)
c.291_294delTACT, p.Thr98Phefs*19 homoz. 1 (14)
c.3G>C, p.Met1Ile het. 1 (14)
(Continued)
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TABLE 1 | Continued
Country Patient genotype Number of cases Study
c.878G>T, p.Ser293Ile het. 1 (14)
c.853-1G>A homoz. 1 (25)
Saudi Arabia c.422C>T, p.Ser141Phe homoz. 5 (26) (26)
Deletion exon 1-3 homoz. 1 (26)
c.530A>G, p.Asn177Ser het / c.1013T>G, p.Leu338Arg het. 2 (26)
c.681G>A, p.Glu227* homoz. 3 (26)
c.922G>A, p.Gly308Arg homoz. 1 (26)
c.1013T>G, p.Leu338Arg homoz. 6 (26)
Exon12 del 24nt homoz. 1 (26)
FIGURE 2 | CTNS gene structure and visualization of alleles detected in individuals of Middle-Eastern ethnical origin. (A) Visualization of the genomic location of CTNS
and genomic breakpoints of the 57 kb deletion. (B) Localizations of CTNS alleles described in cystinosis patients from the Middle East.
WES to establish a molecular diagnosis to optimize the
therapeutic approach in knowledge of the underlying condition
as well as in light of being able to offer genetic counseling
for the family.
WES data filtering was performed as described in the
Methods section of this manuscript. No promising homozygous
variant in known tubulopathy genes were identified amongst
the SNVs or INDELs remaining after filtering. We therefore
proceeded to inspect the BAM file for homozygous deletions
in known tubulopathy genes and, somewhat surprisingly,
detected a large homozygous deletion encompassing the CTNS
gene (Figure 1). Sanger sequencing confirmed this deletion
which spans from exon 10 of the CTNS gene to intron
2/3 of TRPV1, encompassing CARKL/SHP but sparing any
coding sequence of TRPV1 gene (Figure 1). This deletion
has been previously reported as European founder allele
but has not been detected in Middle-Eastern cystinosis
patients before. Unfortunately, no DNA of the parents of
the index case or the deceased sibling was available for
genetic testing.
DISCUSSION
We describe a case clinically presenting with proximal renal
tubular dysfunction as suggested by proteinuria and glucosuria
as well as polydipsia, polyuria, vomiting, failure to thrive, and
mild hypokalemia. However, blood gas analysis revealed very
mild alkalosis, likely with a respiratory component possibly due
to screaming of the child during blood draw as indicated by low
CO2 in combination with low HCO3–. This caused confusion
amongst the admitting local clinicians with regards to the
precise underlying condition of the tubular disore as (metabolic)
alkalosis would rather be compatible with Bartter Syndrome
while metabolic acidosis would be expected in nephropathic
cystinosis. Mild hypophosphatemia was noted at a repeat hospital
visit in Iran but the patient never developed a clinical picture
of rickets. In combination with limited clinical information of
his older sibling who passed away after he developed ESRD,
we decided to perform WES as first line diagnostic test instead
of single gene analyses of known Bartter and renal fanconi
syndrome genes. This resulted in the identification of the
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previously described homozygous 57-kb deletion comprising
nearly the entire CTNS gene and led to the clinical diagnosis
of infantile nephropathic cystinosis in the family. This allele
is very frequent in Northern European/Northern American
populations of European ancestry due to a German founder
mutation originating around 500 AD (15). In other populations
this allele is less often identified and previously published reports
suggested it doesn’t contribute to Cystinosis in the Middle
East. However, largely unavailable genetic testing and incomplete
clinical data in developing countries creates a significant gap
in the rate of cystinosis diagnosis between developed and
developing countries (16).
CTNS mutation surveys of Cystinosis in the Middle East
population including Iran, Turkey, Saudi Arabia, Egypt, and
Jordan have been summarized in Table 1 with mutation
localization to CTNS on protein level displayed in Figure 2. The
most commonly identified CTNS allele in Iranian individuals
was the c.681G>A (p.Glu227∗) variant and together with
the c.922G>A (p.Gly308Arg), c.681G>A (p.Glu227∗) is also
the most common variant in the Saudi Arabia population.
In Jordan, c.890G>A, p.Trp297∗ has been identified in
more than one family. c.451A>G, p.Arg151Gly, c.681G>A
(p.Glu227∗) and 0.834_842del, p. Val279_Tyr281del are the
most common alleles in the Turkish population while in Egypt,
c.829dup, p.Thr277Asnfs∗19 has been reported in 4 different
cases. Interestingly, c.681G>A (p.Glu227∗) is the overall most
frequently identified allele detected in all Middle eastern cohorts
and most variant represent stop or frameshift alleles (Table 1)
(17–22, 26). Studies investigating CTNS mutations in Cystinosis
patients from the Far East have likewise reported several
alleles including compound heterozygous mutation c.329G>C,
c.329+2T>C in Japan, c.926G>A, c.850C>T, c.18-21del/c and
c.969C>G in Thailand, and compound heterozygous mutations
c.329+1del andc.463_464del in China while none of the reported
cases carried the 57-kb deletion (27–29) but a smaller deletion
encompassing ∼20 kb of genomic DNA extending from CARKL
intron 1 to CTNS intron 6, c.771–793del, and a c.1515G>A
variant have been reported in Tunisian nephrotic patients (30).
The 57-kb deletion has however been previously detected in
patients from African American ethnicity (31).
Currently, in Iran as well as many other developing countries,
cystinosis is most often diagnosed by slit lamp examination,
however corneal crystals may not develop until 1–1.5 years of age.
There is therefore a possibility that renal disease may be present
before corneal abnormalities can be noted and a critical treatment
window is left unused. Renal cystinosis symptoms can closely
resemble findings in other tubulopathic diseases such as Dent‘s
disease, Lowe’s syndrome, Bartter syndrome and nephrogenic
diabetes insipidus and without corneal findings, the correct
diagnosis of cystinosis may not be achieved (32). Therefore,
additional easy to access diagnostic tests are required, including
genetic evaluation. Our study highlights the importance to
specifically investigate this allele in non-European populations,
including subjects from Iran. Exome data offers great possibilities
to detect homozygous alleles by visual BAM file inspection,
however heterozygous alleles will be missed by this method and
require CNVs analysis. Nevertheless, slit lamp examination of
the eyes should be used as initial diagnostic test in patients with
clinical suspicion of cystinosis.
As the 57-kb deletion encompasses CARKL/SHPK encoding
sedoheptulokinas enzyme, a recent study has also suggested
measuring activity of the encoded sedoheptulokinas enzyme
if cystinosis is suspected. This test however is not applicable
for patients with other CTNS mutations (33) and given the
rarity of the phenotype, may only be available in large centers.
Genetic workup therefore remains currently the most reliable
and feasible diagnostic method with whole exome sequencing
costs below 500 Euros per sample and available through a
number of commercial companies and Sanger sequencing being
even cheaper.
In summary, while previous studies suggested that the 57.kb
deletion does not play a role in the Middle East, in fact this allele
also needs to be taken into consideration when screening CTNS,
particularly in Iranian patient with Persian ethnicity. As corneal
findings may occur after the onset of renal symptoms which in
turn share common characteristics with other tubulopathies, we
suggest to performWES or NGS gene panel sequencing as a cost-
and time-efficient genetic workup to secure the diagnosis and
enable genetic counseling and prenatal diagnosis.
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